Proteomic analysis of human meibomian gland secretions.

Schepens Eye Research Institute, 20 Staniford Street, Boston, MA 02114, USA.
British Journal of Ophthalmology (Impact Factor: 2.81). 04/2006; 90(3):372-7. DOI: 10.1136/bjo.2005.080846
Source: PubMed

ABSTRACT Human tears contain hundreds of proteins that may exert a significant influence on tear film stability, ocular surface integrity, and visual function. The authors hypothesise that many of these proteins originate from the meibomian gland. This study's aim was to begin to develop the proteomic methodology to permit the testing of their hypothesis.
Meibomian gland secretions were collected from the lower eyelids of adult volunteers and placed in a chloroform-methanol mixture. Samples were partitioned in a biphasic system and non-lipid phase materials were reduced, alkylated, and trypsin digested to obtain peptides for protein identification. This peptide mixture was separated by micro-capillary reverse phase chromatography and the effluent examined by nano-electrospray MS and data dependent MS/MS. SEQUEST software was used to identify proteins from the MS/MS spectra.
The methodological approach to date has permitted the identification of more than 90 proteins in human meibomian gland secretions. Proteins include the alpha2-macroglobulin receptor, IgA alpha chain, farnesoid X activated receptor, interferon regulatory factor 3, lacritin precursor, lactotransferrin, lipocalin 1, lysozyme C precursor, potential phospholipid transporting ATPase IK, seven transmembrane helix receptor (also termed somatostatin receptor type 4), testes development related NYD-SP21 (also termed high affinity IgE receptor beta subunit), and TrkC tyrosine kinase.
These findings indicate that the meibomian gland secretes a number of proteins into the tear film. It is quite possible that these proteins contribute to the dynamics of the tear film in both health and disease.

  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: 350 words maximum: (PLEASE TYPE) Diabetic retinopathy (DR) is a sight threatening disorder which develops in nearly all patients with diabetes mellitus (DM). DR centres on the abnormal growth and rupturing of the retinal blood vessels. Current modes of diagnostics rely on the clinical presentation of DR, at which stage, maturation of the disease and possible damage to the retinal tissue is significant. Due to the high incidence and severity of damage resulting from this disorder a diagnostic which allows early and accurate detection is essential. It was the aim of this project to identify biomarkers in human tears which would provide the basis for development of a non-invasive diagnostic test for DM and DR. This biomarker discovery involved extensive method development for optimal identification of quantitative changes to the tear peptidome and proteome. Proteomic technologies including MALDI-MS, iTRAQ, 2-D LC MS/MS, 2-D electrophoresis, MF10 fractionation and non-labelling mass spectrometry-based strategies were assessed in terms of their utility to investigate the tear proteome and peptidome. This thesis describes the first study to use MF10 technology and peak integration analysis to investigate the peptidome fraction of tears between different subject groups. The application of spin filters to partition higher molecular weight tear proteins from analysis, vastly improved the visualization of lower molecular weight proteins and peptides of human tears using MALDI. It is also the first study to mine the peptidomic population in tears for disease associated biomarkers. From this, one hundred and nine peptides in the 1-25 kDa MF10 fractions of the tear samples were found to alter between DM and DR subjects in comparison to healthy controls. Thirteen of these peptides were sequenced, identified and subsequently validated using an MRM assay developed specifically to quantitate and verify candidate tear peptide biomarkers. The work presented in this thesis is the first study to identify and profile tear peptide biomarkers which have correlated with the onset of DM and DR. It is envisioned that these biomarkers will form the intrinsic components of a non-invasive diagnostic for DM and DR. Furthermore, this work has established principles for future peptidomic or low abundance protein studies with complex bio-fluids. The work has demonstrated that fractionation is an important part of both biomarker discovery and validation, especially in the context of identifying biomarkers in a complex biofluid such as tears. Coupled with validation through targeted quantitative mass spectrometry, the workflow described is a powerful tool of clinical utility in biomarker discovery and validation.
  • [Show abstract] [Hide abstract]
    ABSTRACT: Proteomics and metabolomics investigations of body fluids represent the most challenge for biomarker discovery of several diseases. The search for biomarkers is actually conducted in different body fluids, even if the ideal biomarker should be found in a easily accessible biological fluid, because, if validated, the biomarker could be sought in the healthy population. In this vision tears could be considered an optimum material obtainable by non invasive procedures. In the last years, there was more interest from the scientific community in the study of tears for the research of new biomarkers not only for ocular diseases. In this review we provide a discussion on the current state of biomarkers research in tears and their relevance for clinical practice, reporting the main results of clinical proteomics studies on systemic and eye diseases. We summarize the main methods for tear samples analyses reporting recent advances in "omics" platforms for tears investigations. Moreover, we want to take stock of the emerging field of metabolomics and lipidomics as a new and integrated approach to study protein-metabolites interplay for biomarkers research, where tears represent a still unexplored and attractive field. This article is protected by copyright. All rights reserved. This article is protected by copyright. All rights reserved.
    Proteomics. Clinical applications 02/2015; 9(1-2). DOI:10.1002/prca.201400084 · 2.68 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Purpose: We hypothesize that culturing immortalized human meibomian gland epithelial cells in serum-containing medium will induce their differentiation. The purpose of this investigation was to begin to test our hypothesis, and explore the impact of serum on gene expression and lipid accumulation in human meibomian gland epithelial cells. Methods: Immortalized and primary human meibomian gland epithelial cells were cultured in the presence or absence of serum. Cells were evaluated for lysosome and lipid accumulation, polar and neutral lipid profiles, and gene expression. Results:Our results support our hypothesis that serum stimulates the differentiation of human meibomian gland epithelial cells. This serum-induced effect is associated with a significant increase in the expression of genes linked to cell differentiation, epithelium development, the endoplasmic reticulum, Golgi apparatus, vesicles and lysosomes and a significant decrease in gene activity related to the cell cycle, mitochondria, ribosomes and translation. These cellular responses are accompanied by an accumulation of lipids within lysosomes, as well as alterations in the fatty acid content of polar and nonpolar lipids. Of particular importance, our results show that the molecular and biochemical changes of immortalized human meibomian gland epithelial cells during differentiation are analogous to those of primary cells. Conclusions:Overall, our findings indicate that immortalized human meibomian gland epithelial cells may serve as an ideal preclinical model to identify factors that control cellular differentiation in the meibomian gland.
    Investigative Ophthalmology &amp Visual Science 05/2014; 55(6). DOI:10.1167/iovs.13-13407 · 3.66 Impact Factor

Full-text (2 Sources)

Available from
May 29, 2014